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Case 1
A 16-year-old, 6.8 kg, castrated male DomesticShort-haired cat was presented to Louisiana State
University Veterinary Teaching Hospital with a 3-day
history of progressive ataxia, tetraparesis, and altered
mentation. The owner did not report having observed
evidence of polyuria or polydipsia. The cat had been
diagnosed with hypertrophic cardiomyopathy (HCM)
4 years earlier and was receiving atenolol, benazepril,
and aspirin. Dull mentation, patchy truncal alopecia,
and a grade III of VI systolic heart murmur were noted
during the physical examination. The neurologic exami-
nation revealed ambulatory tetraparesis that was more
severe in the pelvic limbs, plantigrade stance, proprio-
ceptive deficits in all limbs, and positional vertical nys-
tagmus. The CBC, biochemistry profile, and abdominal
ultrasound were unremarkable. The blood glucose con-
centration measured with the chemistry analyzer was
130 mg/dL (7.2 mmol/L). Subsequent blood glucose
measurements (n = 6) using a glucometer validated for
use in catsa ranged from 122 mg/dL (6.7 mmol/L) to
159 mg/dL (8.7 mmol/L) during the 5-day period the
cat was hospitalized. These blood glucose concentra-
tions combined with a normal serum fructosamine con-
centration (228 lmol/L, RI 192–288) ruled out overt
diabetes mellitus (DM).
Two-dimensional echocardiogram revealed severe
asymmetric septal hypertrophy (8.7 mm in diastole).
The left atrium was normal in size and all valves
appeared normal. Continuous wave Doppler through
the left ventricular outflow tract revealed dynamic out-
flow tract obstruction. Color Doppler demonstrated
marked turbulence in the left ventricular outflow tract
and a narrow eccentric jet of mitral regurgitation asso-
ciated with systolic anterior motion of the mitral valve.
Magnetic resonance imaging (MRI)b images of the
head were obtained in multiple planes prior to and fol-
lowing contrastc administration at a dose of 0.1 mmol/kg.
In the region of the pituitary gland, there was a T2
hyperintense, T1 hypointense nodule having marked uni-
form contrast enhancement (Fig 1). This nodule had
moderate extension dorsal to the sella turcica and was
increased in size compared to a normal pituitary gland:
length (0.63 cm), width (0.83 cm), and height (0.85 cm).
On T2* weighted (gradient recalled echo) images, some
regions of reduced signal and small signal voids were pre-
sent within the pituitary gland, mostly on the left side,
consistent with magnetic susceptibility likely due to
regions of hemorrhage within the nodule. Additionally,
there was moderate dilation of the entire ventricular sys-
tem with most severe ventricular enlargement occurring in
the fourth ventricle, which caused dorsal elevation and
compression of the cerebellum. Findings were most con-
sistent with a pituitary macroadenoma, hydrocephalus,
and hydrosyringomyelia. The degree of pituitary enlarge-
ment and severity of 4th ventricular dilation did not sup-
port obstruction due to the pituitary mass. A cystic
accumulation of cerebrospinal fluid (CSF) within the 4th
ventricle or obstructive hydrocephalus due to an addi-
tional lesion not visible on the MRI could not be ruled
out.
A clinical diagnosis of hypersomatotropism was sup-
ported by the presence of a pituitary mass and a total
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Case Report
J Vet Intern Med 2016;30:1216–1221
serum Insulin-like growth factor 1 (IGF-1) concentration
(radioimmunoassay) consistent with the presence of
excess growth hormone (GH) secretion (855 ng/mL, RI
<700). The cat was humanely euthanized approximately
8 days after the initial presentation due to a lack of
response to medical management, which included
corticosteroid treatment, mannitol, furosemide, and a
proton-pump inhibitor.
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Fig 1. Axial MRI images of the brain show a large nodule that is hyperintense on T2W images (A, white arrow), mildly hypointense on
T1W images (C, white arrow), and strongly uniformly contrast enhancing (D, white arrow) in the region of the pituitary gland. A T2* gra-
dient recalled echo sequence shows patchy regions of indistinct hypointensity (B, white arrow) with a small region of marked hypointensity
or signal void (B, black arrow).
Fig 2. Neoplastic cells vary in their intensity of eosinophilic cytoplasmic staining with many cells resembling acidophils (A). Hematoxylin
eosin staining, bar = 200 lm. Neoplastic cells have diffuse cytoplasmic labeling for growth hormone (B), adrenocorticotropic hormone (C),
and follicle-stimulating hormone (D). Small numbers of cells within the neoplasm were positively labeled for melanocyte-stimulating hor-
mone (E), while labeling for thyroid-stimulating hormone (F) was not observed. DAB, hematoxylin counterstain, bar = 100 lm.
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Histology revealed expansion of the pars distalis by a
0.5 cm diameter, unencapsulated densely cellular
neoplasm. The neoplasm was composed of cords and
packets of polygonal cells separated by blood filled
sinusoids and supported on a fine fibrovascular stroma.
Neoplastic cells had oval nuclei with finely stippled
chromatin, and a variable amount of finely granular
eosinophilic cytoplasm with indistinct cell borders
(Fig 2). The cells exhibited mild to moderate anisocyto-
sis and anisokaryosis with a low mitotic index (<1/10
high powered fields), consistent with a pituitary
adenoma.
Immunohistochemistry of the neoplasm (Fig 2)
revealed strong positive cytoplasmic labeling for GH,
which supports a diagnosis of hypersomatotropism
caused by a GH secreting pituitary adenoma. Addition-
ally, there was strong positive labeling for ACTH and
follicle-stimulating hormone (FSH) as well as a small
number of cells within the neoplasm that were positively
labeled for melanocyte-stimulating hormone (MSH).
Cells with positive labeling for thyroid-stimulating hor-
mone (TSH) were not identified in the neoplasm. The
immunohistochemistry findings are consistent with a
plurihormonal adenoma.
Case 2
A 9-year-old, 7 kg, castrated male Domestic Short-
haired cat was presented to Queen Mother Hospital for
Animals at the Royal Veterinary College with a
2-month history of weight gain despite a normal appe-
tite. The owner elected to have the cat evaluated for
this reason and because a sibling had been previously
diagnosed with hypersomatotropism-induced DM. The
physical examination was unremarkable except for
broad facial features. The CBC and biochemistry profile
were unremarkable. The blood glucose measured at the
time of admission using a handheld glucometera was
251 mg/dL (13.8 mmol/L). The serum fructosamine
concentration measured initially and approximately
3 weeks later were both within reference range (233 and
259 lmol/L, respectively, RI 205–322 lmol/L). A repeat
blood glucose concentration measured on a chemistry
analyzerd prior to surgery was 165 mg/dL (9.1 mmol/L).
The urinalysis revealed a urine specific gravity (USG) of
1.038 and no detectable glucose. The recheck blood glu-
cose concentration, normal fructosamine concentrations,
absence of clinical signs compatible with DM, and lack
of glucosuria support stress hyperglycemia as the likely
cause of isolated hyperglycemia. Two-dimensional
echocardiogram revealed mild left ventricular free wall
hypertrophy (6.5 mm in diastole).
A diagnosis of hypersomatotropism was supported
by an increased IGF-1 concentration (1468 ng/mL, RI
<700) and subsequent documentation of increased pitu-
itary length (0.63 cm), width (0.65 cm), and height
(0.4 cm) with contrast-enhancede (2 mL/kg by hand
injection) computed tomographyf (CT) (Fig 3).
Hypophysectomy was performed, and the pituitary was
removed in several pieces. The small pieces were sub-
mitted for histology, which revealed nervous tissue most
consistent with pars nervosa bordered by a densely cel-
lular proliferation of acidophilic cells. The cells had
indistinct borders, finely vacuolated eosinophilic cyto-
plasm, and large round to oval nuclei, with stippled
chromatin and variably prominent nucleoli. The cells
were arranged in sheets and displayed mild to moderate
anisocytosis, anisokaryosis, and cellular pleomorphism.
Immunohistochemistry of the pituitary mass revealed
positive cytoplasmic labeling for GH as well as strong
positive labeling for ACTH, FSH, and MSH consistent
with a plurihormonal adenoma. A clinical diagnosis of
hypersomatotropism caused by a GH secreting pituitary
adenoma was established on the basis of an increased
IGF-1 concentration, pituitary enlargement on CT scan,
and the histopathology findings. An inability to control
progressive epistaxis that developed post-hypophysectomy
resulted in humane euthanasia. A postmortem examina-
tion was declined.
Case 3
A 16-year-old, 7 kg, castrated male Domestic Short-
haired cat was presented to Queen Mother Hospital for
Animals at the Royal Veterinary College with a 5-day
history of generalized seizures. The owner had not
observed and did not report polyuria or polydipsia. The
physical examination revealed mild palmigrade and
plantigrade stance and mild pelvic limb muscle atrophy.
The neurological examination was unremarkable. The
CBC and biochemistry profile were unremarkable with
the exception of hyperglycemia 345 mg/dL (19 mmol/
L). The urinalysis revealed glucosuria (3+) and a USG
of 1.031. Absence of clinical signs suggestive of DM
(i.e., weight loss, polyphagia, polyuria, and polydipsia)
at the time of presentation and a normal serum fruc-
tosamine concentration (253 lmol/L, RI 205–322) make
stress the most likely cause of hyperglycemia and resul-
tant glucosuria.
MRIg images of the head before and after the admin-
istration of gadoliniumh at a dose of 28 mg/kg revealed
pituitary enlargement: length (0.76 cm), width
Fig 3. Postcontract CT image shows mild enlargement of the
pituitary gland (white arrow).
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(0.65 cm), and height (0.59 cm). The region of the pitu-
itary was mildly T2 hyperintense, T1 hyperintense, and
strongly contrast enhancing (Fig 4). A round area
within the left aspect of the pituitary gland was hypoin-
tense to surrounding region of the pituitary on the T1
and T2 weighted images. This same region had reduced
contrast enhancement on postcontrast T1 weighted
images when compared to the surrounding pituitary.
Additionally, a focal extra-axial intracranial mass over-
lying the left temporal lobe, demonstrating marked con-
trast enhancement with a dural tail sign, compatible
with a meningioma was seen. Pituitary enlargement
combined with an increased IGF-1 concentration
(1902 ng/mL, RI <700) supported a diagnosis of con-
current hypersomatotropism. Approximately 1 month
after the initial evaluation, a craniotomy was performed
to resect the left temporal lobe tumor. Histology of the
tumor was consistent with a fibroblastic meningioma.
Phenobarbital was administered postoperatively for
approximately 4 weeks. Transition to a high protein
and low carbohydrate dieti was attempted but was not
successful due to an unwillingness of the cat to consume
the diet. The cat subsequently developed DM 3 months
after the initial presentation and insulin treatment was
prescribed. The owner declined treatment specifically
targeting hypersomatotropism and the cat was huma-
nely euthanized approximately 17 months later. A post-
mortem examination was declined.
This case series presents three cats with GH-secreting
pituitary adenomas that developed hypersomatotropism
without concurrent DM. Hypersomatotropism is a state
of excessive production and secretion of GH, which in
the cat has been described to be the result of a pituitary
acidophilic adenoma, carcinoma, or hyperplasia.1–4 Cur-
rently, most cats are diagnosed with hypersoma-
totropism once they are found to be insulin-resistant
unless the clinician routinely screens all diabetic cats for
hypersomatotropism shortly after DM is diagnosed.
According to screening studies performed in the UK
that measured IGF-1 concentrations in a large number
of diabetic cats, as many as 26–32% were determined
to have hypersomatotropism-induced DM.2,4,5 The
reason that hypersomatotropism has not been previ-
ously reported in cats that are not diabetic is likely
because there is a strong and long-standing clinical
association between DM and the recognizable physical
characteristics of acromegaly. The non-diabetic aspects
of this clinical image are slow to appear, often subtle,
and can go unrecognized.4
It was not possible to directly demonstrate increased
GH concentrations in these cases because a validated
method for measuring feline GH was not commercially
available at the time these cases were evaluated; how-
ever, the diagnosis of hypersomatotropism in both peo-
ple and cats is routinely made by demonstrating an
increased IGF-1 concentration and presence of a pitu-
itary mass or enlargement. In fact, recent practice
guidelines for physicians recommend against relying on
random GH concentrations to diagnose acromegaly in
people.6 Human assays for feline IGF-1 have been vali-
dated, are readily available, and are useful for screening
because IGF-1 reflects 24-hour GH secretion, parallels
changes in GH, and is a sensitive marker for GH
excess.4,7–10 Unlike GH, IGF-1 secretion is not pulsatile
which allows a single sample collected at any point dur-
ing the day to have diagnostic utility. It is generally
accepted that an IGF-1 concentration >1000 ng/mL is
strongly suggestive of acromegaly in cats, with a posi-
tive predictive value of 95%.1,2,4 The first cat in this ser-
ies had immunohistopathologic confirmation of a GH
producing pituitary adenoma, but had an IGF-1 below
this cutoff. This case supports recent speculation that
the currently used arbitrary IGF-1 cutoff value of
1000 ng/mL is too high, underestimates the true preva-
lence of hypersomatotropism, and leads to underdiag-
nosis of mild or early forms of the disease.1,7 This has
led some authors to recently suggest considering
800–1000 ng/mL as a “gray zone” that warrants further
investigation.7 Although the negative predictive value of
an IGF-1 < 1000 ng/mL is low, a case of hypersoma-
totropism-induced DM with a lower IGF-1 was recently
reported4 further supporting the existence of cats with
hypersomatotropism that have IGF-1 concentrations
below the currently accepted cut-off.
A B C
Fig 4. Axial MRI images of the brain show enlargement of the pituitary gland that is mixed hyper and hypo intense on T2W images
(A, white arrow), predominantly hyperintense on T1W images (B, white arrow), and strongly contrast enhancing (C, white arrow).
A region within the left aspect of the pituitary gland was hypointense to surrounding pituitary on both the T1 and T2 W images. This
same region had reduced contrast enhancement on postcontrast T1W images when compared to the surrounding pituitary. A focal, broad
based, mildly T2 hypointense, T1 isointense, markedly uniformly contrast enhancing extraaxial mass with regional vasogenic edema is also
noted in the left temporal lobe and internal capsule (A–C, black arrow).
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It could be argued that the cats being reported were
not diabetic because they had incidental or nonfunc-
tional pituitary enlargement; however, the elevated
serum IGF-1 concentrations and immunohistochemistry
findings argue against such theory, as does the low inci-
dence of incidental pituitary enlargements found in cats.
A recent study reported on a cohort of 62 cats undergo-
ing CT imaging for reasons other than pituitary visual-
ization found only one cat (1.6%) with incidental
pituitary enlargement.4 Finally, cat 3 ultimately became
diabetic.
There were also clinical features that could be com-
patible with the presence of hypersomatotropism: the
weight gain seen in cat 2 and the ventricular myocardial
hypertrophy and cardiac changes in cats 1 and 2. Addi-
tionally, on retrospective MRI assessment of the head
features of cat 3, there was increased parietal bone
thickness and increased distance between the lateral
aspects of the zygomatic arches. These changes have
been described in cats with hypersomatotropism.11
The immunohistochemistry findings of cat 1 and cat
2 were consistent with plurihormonal expression across
three lineages of adenohypophysial differentiation (ie,
corticotrophs, somatotrophs, gonadotrophs). Although
plurihormonal expression in pituitary adenomas has
been described in people and other domestic animals,
there is only a single report of a somatotroph and corti-
cotroph pituitary double adenoma in a cat with DM
and hyperadrenocorticism.12,13 It has been speculated
that plurihormonal expression may be more common,
but tumors are rarely analyzed immunohistochemically
and instead classified by the hormone that dominates
the clinical picture. It is important to note that
although cat 1 and cat 2 had strong positive labeling
for ACTH, neither cat had characteristic features asso-
ciated with hyperadrenocorticism or ultrasonographic
evidence of adrenomegaly. In addition, adrenomegaly
was not identified during the postmortem examination
of cat 1.
To our knowledge, the only discussion of a nondia-
betic acromegalic cat was an author’s personal experience
that was included in a textbook chapter.14 This has
resulted in the dogma that all hypersomatotropic cats are
insulin-resistant diabetics. It is this dogma and the idea
of a “typical” acromegalic phenotype that has likely
resulted in very few cats being screened for hypersoma-
totropism prior to the development of insulin-resistant
DM and an acromegalic phenotype. As a result, the true
prevalence in nondiabetic cats remains unknown. As in
humans, feline hypersomatotropism likely has a gradual-
onset and a period during which the GH and IGF-1 con-
centrations are increased, but DM and signs constituting
the syndrome of acromegaly have yet to occur. If the cat
does not have dysfunctional pancreatic beta cells, as is
suggested to be the case in Type 2 DM, it is likely able to
withstand a period of increasing insulin resistance with-
out developing overt DM. This is further substantiated
by the fact that most diabetic cats with hypersoma-
totropism will enter diabetic remission once the soma-
totrophinoma is removed.5,15 It is also worth noting that
approximately 2/3 of people diagnosed with
hypersomatotropism do not become diabetic,16 further
suggesting that by focusing only on the diabetic popula-
tion, we could be missing hypersomatotropic cats prior
to the development of overt DM as well as those that
may never become diabetic.
With recent evidence of a much higher prevalence of
hypersomatotropism in diabetic cats than once real-
ized1,2,4,17–19 and an unknown prevalence in cats with-
out DM, more work needs to be done to accurately
determine the significance of this endocrinopathy in the
general cat population. Hopefully, increased awareness
and screening will lead to earlier detection and may
allow the occurrence of the syndrome of acromegaly,
DM, and conditions associated with progressive pitu-
itary enlargement to be delayed or prevented. Finally,
recent advances in our ability to treat hypersoma-
totropism (e.g., increasing availability of hypophysec-
tomy, stereotactic radiation and Gamma Knife
technology, and pasireotide) make early diagnosis and
intervention more desirable.
Footnotes
a AlphaTrak and AlphaTrak2, Zoetis, Florham Park, NJ
b Echelon 1.5T, Hitachi Medical Systems America, Twinsburg,
OH
c Magnevist, Bayer Healthcare, Wayne, NJ
d Stat Profile pHOx Ultra, Nova Biomedical Corporation, Wal-
tham, MA
e Omnipaque 350, GE Healthcare Ireland, Cork, Ireland
f Mx8000 IDT 16, Philips, Amsterdam, NL
g Intera 1.5T, Philips Healthcare, Eindhoven,NL
h Dotarem, Guerbet, Milton Keynes, UK
i Hill’s Prescription Diet m/d Feline, Hill’s (registered trademark)
Pet Nutrition, Inc., Topeka, KS, USA
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